PMID- 30835327
OWN - NLM
STAT- MEDLINE
DCOM- 20200310
LR  - 20210511
IS  - 1898-018X (Electronic)
IS  - 1897-5593 (Print)
IS  - 1898-018X (Linking)
VI  - 26
IP  - 2
DP  - 2019
TI  - Effect of coenzyme Q10 in Europeans with chronic heart failure: A sub-group 
      analysis of the Q-SYMBIO randomized double-blind trial.
PG  - 147-156
LID - 10.5603/CJ.a2019.0022 [doi]
AB  - BACKGROUND: Geographical differences in patient characteristics, management and 
      outcomes in heart failure (HF) trials are well recognized. The aim of this study 
      was to assess the consistency of the treat- ment effect of coenzyme Q10 (CoQ10) 
      in the European sub-population of Q-SYMBIO, a randomized double-blind 
      multinational trial of treatment with CoQ10, in addition to standard therapy in 
      chronic HF. METHODS: Patients with moderate to severe HF were randomized to CoQ10 
      300 mg daily or placebo in addition to standard therapy. At 3 months the primary 
      short-term endpoints were changes in New York Heart Association (NYHA) functional 
      classification, 6-min walk test, and levels of N-terminal pro-B type natriuretic 
      peptide. At 2 years the primary long-term endpoint was major adverse 
      cardiovascular events (MACE). RESULTS: There were no significant changes in 
      short-term endpoints. The primary long-term endpoint of MACE was reached by 
      significantly fewer patients in the CoQ10 group (n = 10, 9%) compared to the 
      placebo group (n = 33, 27%, p = 0.001). The following secondary endpoints were 
      significantly improved in the CoQ10 group compared with the placebo group: 
      all-cause and cardiovascular mortality, NYHA classification and left ventricular 
      ejection fraction (LVEF). In the European sub-population, when compared to the 
      whole group, there was greater adherence to guideline directed therapy and 
      similar results for short- and long-term endpoints. A new finding revealed a 
      significant improvement in LVEF. CONCLUSIONS: The therapeutic efficacy of CoQ10 
      demonstrated in the Q-SYMBIO study was confirmed in the European sub-population 
      in terms of safely reducing MACE, all-cause mortality, cardiovascular mortality, 
      hospitalization and improvement of symptoms.
FAU - Mortensen, Anne Louise
AU  - Mortensen AL
AD  - annelou.mortensen@gmail.com.
FAU - Rosenfeldt, Franklin
AU  - Rosenfeldt F
AD  - Faculty of Health, Arts and Design, Swinburne University of Technology, 
      Melbourne, Australia.
AD  - Baker Heart and Diabetes Institute, Melbourne, Australia.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
AD  - 1st Department of Cardiology, Medical University of Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20190305
PL  - Poland
TA  - Cardiol J
JT  - Cardiology journal
JID - 101392712
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (Vitamins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 1339-63-5 (Ubiquinone)
RN  - EJ27X76M46 (coenzyme Q10)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Chromatography, High Pressure Liquid
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Europe/epidemiology
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/blood/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Prospective Studies
MH  - Stroke Volume/*physiology
MH  - Survival Rate/trends
MH  - Treatment Outcome
MH  - Ubiquinone/administration & dosage/*analogs & derivatives/pharmacokinetics
MH  - Ventricular Function, Left/physiology
MH  - Vitamins/administration & dosage/pharmacokinetics
PMC - PMC8086660
OTO - NOTNLM
OT  - chronic heart failure
OT  - coenzyme CoQ10
OT  - hospitalization
OT  - major adverse cardiovascular events
OT  - mortality
OT  - randomized controlled trial
OT  - ubiquinone
COIS- Conflict of interest: None declared
EDAT- 2019/03/06 06:00
MHDA- 2020/03/11 06:00
PMCR- 2019/04/26
CRDT- 2019/03/06 06:00
PHST- 2019/01/31 00:00 [received]
PHST- 2019/02/05 00:00 [accepted]
PHST- 2019/03/06 06:00 [pubmed]
PHST- 2020/03/11 06:00 [medline]
PHST- 2019/03/06 06:00 [entrez]
PHST- 2019/04/26 00:00 [pmc-release]
AID - VM/OJS/J/62920 [pii]
AID - cardj-26-2-147 [pii]
AID - 10.5603/CJ.a2019.0022 [doi]
PST - ppublish
SO  - Cardiol J. 2019;26(2):147-156. doi: 10.5603/CJ.a2019.0022. Epub 2019 Mar 5.